Trial reportDrug design, development and therapy2026
Effect of a Single Subanesthetic Dose of Esketamine on Gastrointestinal Recovery After Laparoscopic Colorectal Cancer Surgery: A Randomized, Outcome-Assessor-Blinded, Placebo-Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Postoperative gastrointestinal dysfunction (POGD) and Postoperative gastrointestinal intolerance (POGI) remain a critical challenge in abdominal surgery, particularly for colorectal cancer patients undergoing laparoscopic procedures. Current evidence suggests anesthetic agents may influence gastrointestinal recovery, yet the impact of esketamine remains underexplored. This trial aimed to investigate whether intraoperative esketamine administration accelerates gastrointestinal function recovery. Methods: In this single-center, randomized, outcome-assessor -blind trial, 104 patients (aged 18-75, ASA I-III) scheduled for elective laparoscopic colorectal cancer surgery were allocated to receive either intravenous esketamine (0.2 mg/kg) or saline (control) 30 minutes before surgery completion. Primary outcome was time to first flatus; secondary outcomes included I-FEED scores, defecation time, oral intake tolerance, and postoperative complications assessed within seven days after surgery. Results: The esketamine group demonstrated significantly shorter time to first flatus (52 [50.25-53.75] vs 60 [58.59-61.41] hours; P < 0.001) and first defecation (87 [81.96-92.04] vs 95 [92.65-97.35] hours; P = 0.04) compared to controls. I-FEED scores were markedly lower (median 1 [0.25-2] vs 2.5 [1-3]; P < 0.001), with reduced nausea (P = 0.001) and abdominal distension duration (P < 0.001). Esketamine also improved postoperative sleep quality, but did not affect hospitalization costs or length of stay. Conclusion: Intraoperative esketamine accelerates gastrointestinal function recovery after laparoscopic colorectal surgery, especially reducing postoperative gastrointestinal intolerance symptoms of nausea and distension while improving early sleep quality. However, no evident benefit was observed in reducing hospital length of stay or patient costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.